氢化可的松局部注射加^(90)Sr-^(90)Y同位素敷贴抑制大鼠皮肤瘢痕形成机制分析  

Analysis of the mechanism of hydrocortisone local injection plus ^(90)Sr-^(90)Y isotope application in inhibiting skin scar formation in rats

作　　者：张芬 戴耕武[1] 杨镓宁[1] 罗东升[1] 赖小梅[1] ZHANG Fen;DAI Gengwu;YANG Jianing;LUO Dongsheng;LAI Xiaomei(Department of Dermatology,Sichuan Provincial People's Hospital,Chengdu,Sichuan 610031,China)

机构地区：[1]四川省人民医院皮肤外科,四川成都610031

出　　处：《安徽医药》2021年第9期1885-1888,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探索氢化可的松局部注射加放疗抑制皮肤瘢痕形成的效果及机制。方法首先制备30只SD大鼠瘢痕模型,并采用随机数字表法分为对照组、糖皮质激素组、糖皮质激素+放疗组,每组各10只;对照组不采取任何治疗措施,糖皮质激素组采用2.5%醋酸氢化可的松注射液(25 g/L)注射治疗,共2个疗程,糖皮质激素+放疗组采用2.5%醋酸氢化可的松注射液(25 g/L)局部注射联合^(90)Sr-^(90)Y敷贴放疗的方法,共2个疗程,两组均从术后第14天开始采取治疗措施,治疗过程中,每天记录瘢痕的长度、宽度及是否产生增生的变化;术后第30天,将大鼠杀死,取瘢痕组织,并通过蛋白质印迹法测量瘢痕组织中Smad3蛋白表达水平,酶联免疫吸附测定(ELISA)检测瘢痕组织中转化生长因子-β1(TGF-β1)和转化生长因子激活激酶1(TAK1)的表达水平。结果手术后第29天,对照组的瘢痕长度为(18.55±2.31)mm,宽度为(7.3±1.13)mm,80%出现了瘢痕增生;糖皮质激素组的瘢痕长度为(15.39±2.17)mm,宽度为(4.7±1.25)mm,60%出现了瘢痕增生;糖皮质激素+放疗组的瘢痕长度为(10.47±1.92)mm,宽度为(1.3±0.94)mm,20%出现了瘢痕增生。糖皮质激素+放疗组的瘢痕长宽显著小于对照组及糖皮质激素组(均P<0.001),瘢痕增生水平明显轻于对照组及糖皮质激素组(P<0.05)。蛋白质印迹法发现,糖皮质激素+放疗组的Smad3蛋白表达水平明显低于对照组及糖皮质激素组(均P<0.05)。ELISA法测定TGF-β1和TAK1发现,糖皮质激素+放疗组TGF-β1和TAK1的表达水平分别明显低于对照组及糖皮质激素组(均P<0.05)。结论氢化可的松局部注射联合放疗可通过下调Smad3途径及TGF-β1和TAK1途径抑制瘢痕的形成,效果明显。Objective To explore the effect and mechanism of hydrocortisone local injection plus radiotherapy in inhibiting skin scar formation.Methods SD rat models of scar were established and assigned into control group,glucocorticoid group,and glucocorticoid plus radiotherapy group by random number table method,10 in each group.No control measures were taken in the control group,2.5%hydrocortisone acetate injection(25 g/L)was carried out with 2 courses in the glucocorticoid group,and 2.5%hydrocortisone acetate injection(25 g/L)local injection combined with ^(90)Sr-^(90)Y application radiotherapy were carried out with 2 courses in glucocorticoid plus radiotherapy group.These two groups both started their respective treatments from the 14th day after surgery.During the treatment,the length and width of the scar and whether hyperplasia occurred were recorded every day.On the 30th day after surgery,the rats were sacrificed,the scar tissue was taken,and the expression level of Smad3 protein in the scar tissue was measured by Western Blot analysis.The expression levels of transforming growth factor-β1(TGF-β1)and transforming growth factor-βactivated kinase-1(TAK1)in the scar tissue were determined by enzyme linked immunosorbent assay(ELISA).Results On the 29th day after surgery,the length and width of the scar in the control group were(18.55±2.31)mm,(7.3±1.13)mm,respectively,and hypertrophic scarsaccounted for 80%;the length and width of the scar in the glucocorticoid group were(15.39±2.17)mm,(4.7±1.25)mm,respectively,and hypertrophic scars accounted for 60%;the length and width of the scar in the glucocorticoid plus radiotherapy group were(10.47±1.92)mm,(1.3±0.94)mm,respectively,and hypertrophic scars accounted for 20%.The scar length and width of the glucocorticoid plus radiotherapy group were significantly smaller than those of the control group and glucocorticoid group(both P<0.001),and the scar hypeplasia was lighter(P<0.05).Western blot analysis showed that the expression level of Smad3 protein in the glucocorti

关 键 词：瘢痕 氢化可的松 放疗 SMAD3 转化生长因子-β1 转化生长因子激活激酶1 ^(90)Sr-^(90)Y敷贴放射治疗 大鼠 Sprague-Dawley 

分 类 号：R622[医药卫生—整形外科]